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a b s t r a c t
Background: Osteosarcoma (OS) is the most common type of primary bone cancer affecting children and
adolescents. OS has a high propensity to spread meaning the disease is often incurable and fatal. There
have been no improvements in survival rates for decades. This highlights an urgent need for the devel-
opment of novel therapeutic strategies. Here, we report in vitro and in vivo data that demonstrates the
role of purinergic signalling, specifically, the B isoform of the purinergic receptor P2RX7 (P2RX7B), in
OS progression and metastasis.
Methods: TE85 and MNNG-HOS OS cells were transfected with P2RX7B. These cell lines were then char-
acterised and assessed for proliferation, cell adhesion, migration and invasion in vitro. We used these cells
to perform both paratibial and tail vein injected mouse studies where the primary tumour, bone and
lungs were analysed. We used RNA-seq to identify responsive pathways relating to P2RX7B.
Results: Our data shows that P2RX7B expression confers a survival advantage in TE85 + P2RX7B and
MNNG-HOS + P2RX7B human OS cell lines in vitro that is minimised following treatment with
A740003, a specific P2RX7 antagonist. P2RX7B expression reduced cell adhesion and P2RX7B activation
promoted invasion and migration in vitro, demonstrating a metastatic phenotype. Using an in vivo OS
xenograft model, MNNG-HOS + P2RX7B tumours exhibited cancer-associated ectopic bone formation
that was abrogated with A740003 treatment. A pro-metastatic phenotype was further demonstrated
in vivo as expression of P2RX7B in primary tumour cells increased the propensity of tumour cells to
metastasise to the lungs. RNA-seq identified a novel gene axis, FN1/LOX/PDGFB/IGFBP3/BMP4, downregu-
lated in response to A740003 treatment.
Conclusion: Our data illustrates a role for P2RX7B in OS tumour growth, progression and metastasis. We
show that P2RX7B is a future therapeutic target in human OS.
 2021 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
OS is the most common type of primary bone cancer affecting
children and adolescents, it is a rare and often fatal disease [1].
OS is highly resistant to radiotherapy, therefore treatment involves
complex chemotherapy and surgery, often amputation. Survival
statistics have remained static with no real advances in treatment
options for decades. The 5-year overall survival rate has remained
static for decades, at 53% for patients under 40 years of age [2],
however, with metastasis this figure decreases to around 20% [3].
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These statistics highlight an urgent need for development of novel
therapeutic strategies for OS treatment.
Purinergic receptors are expressed and play a role in the pro-
gression of several cancers [4]. Several studies have identified ade-
nosine triphosphate (ATP) to be at a high concentration in the
tumour microenvironment [5,6], yet undetectable in surrounding
healthy tissue [7]. These findings are particularly pertinent in the
case of the bone tumour microenvironment where purinergic
receptors are known to be expressed by bone cells that play a
key role in normal bone physiology [8,9] and where mechanical
loading can stimulate ATP release from bone cells [9-11]. ATP
when broken down to adenosine can act as an immunosuppressant
and chemotherapy treatments can cause the release of ATP from
dying cells [12]. This release can modify the tumour microenviron-
ment in favour of cancer growth and potentially result in disease
progression. Purinergic receptor P2RX7 is an ATP gated ion channel
and has received an increasing amount of attention due to both
in vitro and in vivo evidence of its overexpression and function in
carcinogenesis of a range of different tumours, including bone sar-
comas [4,12-19]. P2RX7 contributes to various oncogene-like prop-
erties such as enhancing tumour cell growth [20] and metabolic
activity, increasing invasiveness [21] and metastatic potential by
acting in an autocrine/paracrine manner on surrounding cells and
by acting as a stimulant for the release of angiogenic factors [14].
Nine different naturally occurring human P2RX7 splice variants
(P2RX7A to P2RX7J) have been identified with each showing differ-
ing biological characteristics [22,23]. P2RX7 isoform expression,
phenotype and level of activation can determine the functional role
that P2RX7 has in the tumour microenvironment. The full length
P2RX7A variant has the unique ability to form a large transmem-
brane pore in response to high levels of ATP resulting in cell death
[23]. P2RX7B preserves an intron between exons 10 and 11 that
causes the insertion of a stop codon that eliminates translation of
the last 249 amino acids of the C terminus and the addition of an
extra 18 amino acids after residue 346. These alterations still
enable receptor stimulation by ATP/Benzoyl ATP (BzATP) and
importantly efficacy of P2RX7 antagonists [23]. Of the splice vari-
ants, P2RX7B is unique in that it retains its ability to act as a func-
tional ion channel [23,24] and shares a similar tissue distribution
as the full length receptor [25]. Due to the truncated nature of
the P2RX7B it naturally lacks the pore function with a ‘‘non-
functional” phenotype found to be essential for tumour cell growth
[26] and more recently other features including response to treat-
ment, invasion and promotion of metastasis [27]. In lung adenocar-
cinoma patient samples, high P2RX7B expression correlated with
reduced immune cell infiltration, suggesting it could be a potential
biomarker [28]. Whilst in acute myeloid leukaemia, P2RX7B
expression was increased in relapsing patients and downregulated
in patients in remission, suggesting high levels of P2RX7B may
contribute towards chemoresistance. This was proposed to be
due to the absence of the full-length P2RX7A receptor pore, as
when the full length receptor was present chemotherapy uptake
was increased. The study further showed that treatment in vivo
with combined chemotherapy and P2RX7 antagonist was an effec-
tive strategy acting on both isoforms, reducing tumour growth and
isoform expression in the primary tumour [29].
Previous studies by our lab and others have shown a potential
role for targeting P2RX7 as a therapeutic option in OS [15,30].
When assessing different P2RX7 splice variants in TE85 human
OS cells P2RX7B provided a growth advantage in vitro. In a tissure
microarray of human OS patient samples stained with antibodies
specific to the extracellular or c-terminal region of P2RX7, 27%
stained positive for P2RX7B alone. Further analysis of the samples
revealed that P2RX7B positive osteosarcomas showed a higher cell
density and increased Ki67 positivity indicating a relationship
between P2RX7B expression and enhanced cell proliferation and
that OS phenotypes can be influenced by P2RX7B [15]. More
recently it has been suggested that the full length P2RX7A could
promote OS cell growth and metastasis both in vitro and in vivo
[30]. In this study we have built upon both of these previous stud-
ies and explored the role of the specific P2RX7B splice variant in OS
both in vitro and in vivo.
2. Materials and methods
2.1. Cell culture and transfections
The human OS cell lines HOS-TE85 [31] (referred to herein as
TE85) and MNNG-HOS [32] were kindly provided by Professor
Jim Gallagher (Liverpool, UK) and Professor Dominique Heymann
(INSERM, France), respectively. HEK-293 + P2RX7A cells were
kindly provided from the laboratory of Dr Elena Adinolfi (Ferrara,
Italy). All cell lines were authenticated using STR profiling during
the project period/within the last three years. Cell lines were main-
tained in DMEM+GlutamaxTM (Life Technologies, UK) medium
containing 10% FBS with 1% penicillin/streptomycin antibiotics
(Life Technologies, UK) (referred to as complete medium). TE85
cells previously stably transfected with P2RX7B [15] were main-
tained in complete culture medium plus 0.2 mg/ml hygromycin.
MNNG-HOS cells containing a plasma membrane luciferase (Pme-
LUC) from the lab of Professor Francesco Di Virgilio [33] were fur-
ther transfected with the mammalian expression vector pcDNA3
containing P2RX7B [15] using Lipofectamine and maintained
under 0.8 mg/ml G418 selection for PmeLUC and 0.2 mg/ml hygro-
mycin for P2RX7B. All cells were grown at 37 C in a humidified 5%
CO2 incubator and were regularly mycoplasma tested to ensure
that all experiments were performed with mycoplasma-free cells.
2.2. Fluo-4 DirectTM calcium assay
Changes in intracellular calcium concentrations were measured
using Fluo-4 DirectTM Calcium Assay (ThermoFisher Scientific, UK)
in accordance with the manufacturer’s instructions. In brief,
15,000 cells were loaded with Fluo-4 DirectTM calcium reagent, left
to incubate for 1 h at 37 C before being stimulated with 100 mM
BzATP (Sigma, UK) (based on Agrawal et al 2020, [34]) and then
0.8 mM ionomycin (Sigma, UK). Excitation ratio and emission wave-
lengths were 490 nm and 525 nm respectively.
2.3. Measurement of plasma membrane permeabilization
Increases in plasma membrane permeability were measured by
monitoring ethidium bromide up-take. Briefly,15,000 cells were
incubated at 37 C with or without 10 mM of the A740003 (Tocris,
UK) for 1 h in Hank’s Balanced Salt Solution (HBSS) (ThermoFisher
Scientific, UK). Cells were then stimulated with 300 mM BzATP
(previously shown to activate pore formation [15,34,35]) which
was diluted in ultra-pure ethidium bromide to a final concentra-
tion of 100 mM. Induction of P2RX7 pore formation was then
detected at 360 nm excitation and 580 nm emission for 45 min
after an initial 5-minute baseline reading, with readings taken
every 2 min.
2.4. Proliferation assay
The effect of P2RX7B expression and inhibition on OS cell prolif-
eration was assessed using the CellTiter 96 AQueous One Solution
Cell Proliferation Assay (Promega, UK), TE85, TE85 + P2RX7B,
MNNG-HOS and MNNG-HOS + P2RX7B cell lines were seeded at
5,000 and 2,500 cells per well, respectively, in a 96-well plate in
100 lL phenol-free DMEM (Life Technologies, UK) complete med-
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ium. After 24 h, cells were washed twice with PBS and the medium
was changed to medium containing 0.5% FBS. At each time-point
on days 0, 1, 3, 5 and 7, MTS was diluted 1:5 in phenol-free DMEM
with 100 lL added directly making a total volume of 200 lL. The
cells were incubated for 3 h at 37 C. The absorbance was read at
490 nm using the SpectraMax M5e Microplate Reader (Molecular
Devices, USA). For inhibition studies the same protocol was per-
formed with 100 lM A740004 added after 24 h with absorbance
read at day 3 (based on Giuliani et al., 2014 where A740003 was
shown to effect cell growth at this concentration [15]).
2.5. Cell adhesion assay
96-well plates coated with 50 mg/mL Type 1 rat tail collagen
(Sigma, UK) were seeded with 7,500 cells per well in medium con-
taining 0.5% FBS. After incubation for 4 h at 37 C the wells were
washed 4 times with PBS to removed unattached cells. Cells were
then lysed using 50 mL lysis buffer (20 mM tris, 0.05 M MgCl2) and
Quant-iTTM PicoGreen dsDNA Reagent (ThermoFisher Scientific,
UK) was then added to detect the DNA of the lysed remaining cells.
Fluorescence was detected and quantified at 485 nm excitation
and 530 nm emission.
2.6. Cell migration (scratch assay)
12-well plates were seeded with 200,000 cells in complete
medium and left overnight to form a confluent monolayer. The
medium was then changed to complete medium containing 5 mg/
mL mitomycin C and cells incubated for 2 h at 37 C. A scratch
was then made using a 10 lL pipette tip down the centre of the
well. The wells were washed twice with PBS and fresh 0.5% FBS
medium added. Images were then taken every 2 h for a 24 h period.
For studies activating the P2RX7B 10 mMBzATP was used (based on
previous studies affecting migration in other cell types at this con-
centration [16,36]) in low 0.5% FBS medium. Scratch assay images
were analysed using the automated T-scratch software [37].
2.7. Cell invasion
Matrigel (1.5 mg/mL) was added to Corning FluoroBlok inserts
and left to set for 2 h at 37 C. Cells were incubated with 5 mg/mL
mitomycin C for 2 h before 100,000 cells were added to Matrigel-
coated insert in serum free medium + 10 mM BzATP (based on pre-
vious studies affecting invasion in other cell types at this concen-
tration [16,36]). 10% FBS was used as a chemoattractant in the
lower chamber. After 24 h the transwell inserts were washed twice
in PBS and stained with 5 mM Calcein AM cell permeant dye for
30 min at 37 C. The inserts were then washed twice again in
PBS, imaged and analysed using Image J [38].
2.8. RNA extraction and end point PCR
RNA was extracted from cells using the ReliaPrepTM RNA Mini-
prep System kit in accordance with the manufacturer’s protocol
(Promega, UK). RNA was reverse transcribed using the Applied
BiosystemsTM high capacity RNA to cDNATM Kit in accordance with
the manufacturer’s protocol. End point PCR primers were designed
using Pubmed gene sequences. P2RX7 mRNA expression was
determined with two sets of primers; the first primer set was
designed in the N terminal gene sequence with the forward primer
on the exon boundary between exon 3 and 4 and the reverse
between exon 7 and 8. This region is present on both the full length
and truncated P2RX7B (Forward: 50-TTGTGTCCCGAGTATCCCAC-30
Reverse: 50-TCAATGCCCATTATTCCGCC-30 product length 413 bp,).
The second primer set was designed further along the gene
sequence with the both the forward primer and reverse primer
designed to bind to exon 13 (Forward 50-ACCAGAGGAGATA
CAGCTGC-30 Reverse: 50-TACTGCCCTTCACTCTTCGG-30, product
length 399 bp). This C-terminal region is only present on the full
length P2RX7A and thereby not detected in the cells with the trun-
cated P2RX7B. cDNA was amplified using Promega GoTaq Flexi
DNA polymerase kit with primers (0.5 mM) and template cDNA
added. The PCR samples were denatured for 2 min at 95 C for
one cycle, followed by 35 cycles of denaturation at 90 C for 30 s,
primer annealing temperature for 30 s, and extension at 72 C for
30 s. A final extension was then performed at 72 C for 5 min for
one cycle before samples were held at 4 C.
2.9. Quantitative RT-PCR (qRT-PCR)
qRT-PCR was performed using Taqman probes (Human P2RX7
Taqman gene expression assay, ID: Hs00951600_m1 catalogue:
4351372, human HPRT Taqman gene expression assay, ID:
Hs02800695 catalogue: 1621448) in accordance with the manu-
facturer’s instructions on a Applied Biosystems 7900HT Real-
Time PCR machine (Applied BiosystemsTM).
2.10. RNA-seq of P2RX7B agonist and antagonist treated MNNG-HOS
and MNNG-HOS + P2RX7B OS cell lines
MNNG-HOS and MNNG-HOS + P2RX7B cells were plated in a 6
well plate at a density of 500,000 cells and left for 24 h to adhere.
Cells were then treated with 10 mM BzATP, 10 mM A740003 or both
BzATP and A740003 together (A740003 was pre incubated for 1 h
before adding BzATP), 24 h later RNA was extracted using the miR-
Neasy mini kit (Qiagen, UK) according to the manufacturer’s proto-
col. RNA concentration and integrity were assessed on a NanoDrop
8000 Spectrophotometer (Thermo Fisher Scientific, UK) and RNA
was stored at  80 C. The NEBNext ultra II RNA library prep kit
(New England Biolabs, UK) was used to generate poly(A) + libraries.
Sequencing was performed on a HiSeq 2500 (Illumina, USA) using a
150 bp paired end (PE) metric.
2.11. Bioinformatics
Fastq files were converted to fasta. Trim Galore was used to
remove adapter sequences and reads < 20 nucleotides. Trimmed
reads were aligned to the human genome (v38) using HISAT2
[39]. Transcripts were download from GENCODE (v28) and
Ensembl (v92). Count matrices for transcripts were created using
Kallisto [40]. Differentially expressed (DE) transcripts were deter-
mined using the DESeq2 [41] package in R (v1.2.10). DE mRNA
according to log2 fold change  2, p  0.05 plus false discovery rate
(FDR) < 5% were selected for downstream analysis. Pathway anal-
ysis was used to determine the biological pathways of the different
genes using the KEGG database.
2.12. In silico analysis of OS datasets for P2RX7 expression
A retrospective analysis across publicly available datasets was
performed to identify P2RX7 expression in human OS cell lines.
Searches were performed in the Cancer Dependency Map using
the 20Q4 depmap gene expression dataset (Broad Institute,
https://depmap.org/portal/), R2 Genomics Analysis and Visualiza-
tion Platform using datasets (GSE86109, GSE42352, GSE11414,
GSE124768 (http://r2.amc.nl) and Ordino a visual cancer analysis
database https://ordino.caleydoapp.org/ where the gene P2RX7
was selected and filtered for OS, the identified cell lines were then
selected for analysis.
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2.13. In vivo animal studies
All animal experiments were performed using 7–9-week-old
female BALB/c nude mice (Charles River Margate, UK) that were
acclimatised for at least one week prior to experimental manipula-
tion. Mice were housed in the same environmentally controlled
conditions with a 12 h light/dark cycle at 22 C and free to access
2018 Teklad Global 18% Protein Rodent Diet containing 1.01% Cal-
cium (Harlan Laboratories, UK) and water ad libitum in RB-3 cages.
All procedures complied with the UK Animals (Scientific Proce-
dures) Act 1986 and were reviewed and approved by the local
Research Ethics Committee of The University of Sheffield (Sheffield,
UK). Mice were anesthetized by inhalation of isoflurane and oxy-
gen before injection of 250,000 MNNG-HOS or MNNG-
HOS + P2RX7B cells onto the tibial surface. For inhibition studies,
mice were randomly allocated into treatment groups (N = 11–13
mice/group) 2 days after OS cell injection and received either vehi-
cle (PBS + DMSO), or A740003 (50 mg/kg) by IP injection 3 times a
week for up to 3 weeks. OS tumours were measured by callipers at
the end of the experiment prior to euthanasia, the legs and lungs
were then harvested for analysis. For OS metastasis studies mice
were anesthetized as above before 1.5 million MNNG-HOS or
MNNG-HOS + P2RX7B cells were injected into the tail vein. After
2 days the mice were divided into 4 groups (N = 6 mice/group)
and treated with either vehicle (PBS + DMSO) or A740003 (50 mg/
kg) by IP injection 3 times a week for 3 weeks, after euthanasia
the lungs were harvested.
2.14. Micro-CT analysis
Fixed tibiae were scanned using a SkyScan 1172 desktop lCT
machine (Bruker) at a resolution of 8 lm with the X-ray source
operating at 50 kV, 200lA and using a 0.5 mm aluminium filter
and images were captured every 0.7. Scanned images were recon-
structed using Skyscan NRecon software (v. 1.6.9, Bruker, Belgium).
The region of interest (ROI) for the total bone volume was selected
to include both the tibia and fibula and was determined at the top
of the bone as soon as the tibia enters the image to the lower point
where the tibia and fibula meet.
2.15. Histological studies on the primary tumour
Bones were fixed in neutral buffered formalin for 48 h after
which time they were transferred to 70% ethanol. Bones were then
decalcified in 10% EDTA, embedded in paraffin and 5 lm sections
produced. Sections were then dewaxed in xylene, rehydrated
through graded alcohols before performing heat mediated antigen
retrieval using a water bath at 80 C for 20 min with citrate buffer
at pH6 (Abcam, Cambridge, UK). Endogenous peroxidase was
blocked with 3% hydrogen peroxide (VWR, Lutterworth, UK) for
20 min at room temperature, washed twice in PBS-tween (PBST)
and blocked in 1% Normal goat serum in PBST (Vector Laboratories,
Peterborough, UK) for 20 min at room temperature. Primary rabbit
anti-human Ki-67 antibody (Abcam 1 mg/mL) was added to the
sections at a dilution of 1:100 in 1% casein. Sections were incu-
bated for 1 h at room temperature. After 2 washes in PBST, the sec-
tions were treated with biotinylated goat anti-rabbit IgG secondary
antibody (Vector Laboratories) at 1:200 in 1% casein for 20 min at
room temperature. Sections were washed twice in PBST then trea-
ted with an ABC kit (Vector Laboratories) for 20 min at room tem-
perature and the bound antibody detected with Impact-DAB
substrate-chromagen system (Vector Laboratories) for 5 min at
room temperature. The sections were washed in tap water for
3 min, counter stained in Gills haematoxylin (VWR, Merck, Birm-
ingham, UK) for 5 s, dehydrated through graded alcohols, and
cleared with xylene. Coverslips were mounted using DPX. The
slides were scanned using a Pannoramic 250 Flash III (3D HISTECH,
Budapest, Hungary) and percentage of Ki-67 cells were quantified
using QuPath software [42]. Tumours were further categorised his-
tologically into high or low grade tumours using the median % Ki-
67 value of (20.17%) as a cut off [43].
2.16. Histological studies for lung metastasis
Lungs were collected and fixed in 10% neutral buffered formalin
for 48 h before being changed into 70% ethanol and embedded in
paraffin. To section the lungs 6 lm sections were cut every
100 lm deep to cover the entire lung. Sections were added to
xylene twice for 5 min rehydrated through graded alcohols for
5 min each and tap water for 1 min. The nuclei were then stained
by Gill’s II haematoxylin for 90 s and washed using tap water for
3 min. 1% aqueous eosin (VWR, Merck, Birmingham, UK) with 1%
calcium carbonate (Sigma, UK) used to stain the cytoplasm for
5 min. The slides were then quickly dehydrated through graded
alcohols and cleared with xylene. Coverslips were mounted using
DPX. Lung sections were visualised under a light microscope and
were observed by two independent researchers blinded to the
treatment groups for the presence of any OS metastatic nodules.
2.17. Statistical analysis
All data was analysed using GraphPad Prism v7. Datasets were
tested for normality prior to analysis and statistical significance
was tested using parametric or non-parametric tests as appropri-
ate for the specific dataset. For comparing two groups, either a
paired or unpaired t-test was used depending upon the groups to
be compared. Two-way ANOVA was used to determine the effect
of P2RX7B expression on tumour-induced changes in bone param-
eters in vivo. Slopes were compared using linear regression for the
wound closure migration assay and a Chi-squared was used for Ki-
67 staining.
3. Results
3.1. P2RX7B expression and functional characteristics in OS cells
We have previously shown that the human OS cell line TE85
lacks endogenous P2RX7 protein expression [44] and that overex-
pression of the P2RX7 in this cell line confers trophic activity, with
the most efficient growth-promoting isoform being P2RX7B alone
[15]. To further investigate the role of the P2RX7B in OS pathology
both TE85 and the MNNG-HOS cell line (a chemically transformed
cell line derived from the original TE85 cell line which, unlike TE85
cells, forms tumours in mice in vivo [45]) were utilised. Similar to
TE85 cells, we did not detect endogenous P2RX7 expression in
MNNG-HOS cells at the mRNA transcript level using end point
and qRT-PCR (Fig. 1A & 1B). We also used the Ca2+ influx and pore
formation assays to test for the presence of functional P2RX7, the
results of which support the lack of endogenous P2RX7 in these
cells (Fig. 1C & 1D). We therefore transfected both these cell lines
with the truncated P2RX7B isoform (Fig. 1A & 1B), and confirmed
functional expression using P2RX7 Ca2+ signalling and pore forma-
tion (Fig. 1C & 1D), the latter being unaltered as predicated. To fur-
ther examine the expression of P2RX7 in OS cell lines, we
performed retrospective in silico analysis using publicly available
datasets. DepMap contained P2RX7 gene expression data for 14
OS cell lines, R2 genomics had data for 38 cell lines (across 4 data-
sets) and Ordino had data for 9 cell lines. The data was then
arranged showing P2RX7 expression across the cell lines. From
these datasets the expression data for cell lines relating to the
HOS-TE85 family and its modified derivatives KHOS (viral), MNNG
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(chemical) and 143b (metastatic) [46,47] were consistently low for
P2RX7 expression in comparison to other OS cell lines (Supplemen-
tary Fig. 1A-E). Cell lines that were consistently high for P2RX7
expression were SJSA-1 (Supplementary Fig. 1A-D), CAL72 (Supple-
mentary Fig. 1B & D) and MG63 (Supplementary Fig. 1A-D & F).
3.2. P2RX7B expression increases the growth and metastatic potential
of OS cells
Transfection of P2RX7B into both OS cell lines caused an
increase in proliferation under low serum conditions over a 7-
day period. In TE85 cells transfected with P2RX7B
(TE85 + P2RX7B) there was a growth increase of 33% across day
3 (P = 0.0001), 5 (P = 0.0003) and 7 (P = 0.0011) (Fig. 2Ai). The same
increase in growth was also observed in MNNG-HOS cells trans-
fected with P2RX7B (MNNG-HOS + P2RX7B)  56% increase across
day 3 (P=<0.0001), 5 (P=<0.0001), and 7 (P= <0.0001) (Fig. 2Aiv).
The P2RX7 antagonist A740003 reduced growth increase by 40%
in TE85 + P2RX7B (P= <0.0001, Fig. 2Aii) and 52% in MNNG-
HOS + P2RX7B cells (P= <0.0001, Fig. 2Av). In both cell lines
A740003 had no statistically significant effect on the parental cell
lines not transfected with P2RX7B (Fig. 2Aiii and 2Avi).
To assess the effect of P2RX7B expression on adhesion, type 1
collagen was used as an extracellular matrix (ECM) and the cells
ability to adhere to it was measured. TE85 + P2RX7B cells had a
47% reduction in cell adhesion (P=<0.0001, Fig. 2Bi) and MNNG-
HOS + P2RX7B cells had a 27% reduction in cell adhesion
(P=<0.0001, Fig. 2Bii) compared with their respective controls. To
measure the effect of P2RX7B expression on OS cell migration a
scratch assay was performed where the cells were monitored over
a 24 h period for ‘‘wound” closure. After 24 h under low serum con-
ditions, TE85 + P2RX7B showed a 12% increase in wound closure
compared to TE85 cells and showed an overall difference when
comparing the rate of closure (P=<0.0001, Fig. 2Ci and 2Ciii). This
difference was further increased to 24% when stimulated with
10 mM BzATP (P=<0.0001, Fig. 2Civ). Similarly, MNNG-
HOS + P2RX7B cells showed a 15% increase in wound closure when
stimulated with 10 mM BzATP (P = 0.002, Fig. 2Cii and 2Cvi). To
measure the invasion ability of OS cells a Fluroblok transwell sys-
tem containing matrigel was used with 10% FBS in the lower cham-
ber as a chemoattractant and the cells in the upper chamber
stimulated with 10 mM BzATP as P2RX7B receptor activation was
required to induce increased migration in both OS cell lines. The
TE85 cell line is a relatively non-invasive cell line therefore only
a few detectable cells invaded the transwell (Fig. 2Di). Transfection
with P2RX7B and stimulation with BzATP provided a strong stim-
ulus to promote invasion increasing this from an average of 49 cells
to 298 cells (P = 0.00374, Fig. 2Dii). MNNG-HOS cells showed a
higher level of invasion in keeping with their phenotype
(Fig. 2Diii), with a similar increased invasion seen in the MNNG-
HOS + P2RX7B cells (increasing from an average of 278 cells to
662 cells, P = 0.025, Fig. 2Div).
3.3. Effect of P2RX7B expression and inhibition on tumour growth and
bone disease in an OS mouse model in vivo
To determine whether P2RX7B expression would affect the
growth and progression of OS disease in vivo a murine paratibial
model of OS was used. This model has the advantage of an intact
bone at the outset and results in tumours that reproduce the most
common osteoblastic form of human OS [48-50]. As TE85 cells do
not form tumours in vivo, and this remained the case even after
transfection with P2RX7B (data not shown), we concentrated the
in vivo part of this study using the MNNG-HOS cell lines. Injection
of either MNNG-HOS or MNNG-HOS + P2RX7B cells resulted in the
formation of OS in the tibia (Fig. 3A). There was no statistical differ-
ence in the final tumour size between mice injected with MNNG-
HOS + P2RX7B cells compared to MNNG-HOS cells (P = 0.3071,
Supplementary Fig. 2Ai). The P2RX7 antagonist A740003 had a ten-
dency to reduce the size of the tumours from both cell lines
although this did not quite reach statistical significance
(P = 0.0568 for MNNG-HOS + P2RX7B and P = 0.0516 for MNNG-
HOS; Supplementary Fig. 2Aii and 2Aiii). Ki-67 staining of the
tumours similarly demonstrated no significant difference in the
percentage of cells stained positive in MNNG-HOS + P2RX7B
tumours compared to MNNG-HOS tumours (P = 0.6329 Supple-
mentary Fig. 2Bi) or when either group was treated with
A740003 (P = 0.9074 Supplementary Fig. 2Ci and P = 0.4010 respec-
tively, Supplementary Fig. 2Di). When divided into high and low
grade tumours, there was no difference in the percentage of grades
between the cell lines (P = 0.4201 Supplementary Fig. 3Bii).
When both cells lines were treated with the P2RX7 antagonist
A740003, the ratio of low to high grade tumours had a tendency
to improve in both cell lines, however the association was not sta-
tistically significant, (P = 0.1156 for MNNG-HOS and P = 0.3917 for
MNNG-HOS + P2RX7B respectively Supplementary Fig. 2Cii & 3Dii).
A defining feature of OS is the involvement of the bone itself,
therefore resultant effect on bone was measured using micro-CT.
Injection of OS cells led to the typical ectopic bone formation
(Fig. 3A) with a significant increase in total bone volume of the
injected leg compared to its contralateral leg for both MNNG-
HOS (P = 0.0343, Fig. 3Bi) and MNNG-HOS + P2RX7B cells
(P = 0.0446, Fig. 3Bii). When considering the effect of the cell type
of OS tumour on the bone disease, Two-way ANOVA revealed that
whilst the OS tumour accounted for 7.758% of the variance
(P = 0.0341), expression of P2RX7B in the MNNG-HOS cells
accounted for 13.62% of the variance (P = 0.0058). Treatment with
A740003 reduced the extent of the tumour induced bone disease
both in MNNG-HOS and MNNG-HOS + P2RX7B such that the bone
volume was no longer significantly increased compared to the con-
tralateral leg (P = 0.2939, and P = 0.4783 respectively, Fig. 3B).
3.4. P2RX7B expression increases spontaneous OS lung metastasis
in vivo
To investigate the role of P2RX7B in OS metastasis the lungs
were collected from each mouse from the paratibial model and
3
Fig. 1. Characterising P2RX7B in TE85 and MNNG-HOS OS cells: A) Expression of P2RX7 mRNA in TE85, TE85 + P2RX7B, MNNG-HOS and MNNG-HOS + P2RX7B cells with two
different P2RX7 sets of primers binding to the P2RX7 N Terminal or C terminal, (product length 413 BP and 399 BP respectively) HEK-293 + P2RX7A was used as a positive
control. B) Expression of P2RX7 mRNA in TE85, TE85 + P2RX7B, MNNG-HOS and MNNG-HOS + P2RX7B OS cells using qRT-PCR, HPRT was used as a housekeeping gene. C)
Calcium assays were assessed in TE85, TE85 + P2RX7B, MNNG-HOS and MNNG-HOS + P2RX7B cells by loading 15,000 cells with Fluo-4 DirectTM calcium reagent, left to
incubate for 1 h at 37 C before been stimulated with 100 mM BzATP and then 0.8 mM ionomycin, the response was detected at excitation ratio and emission wavelength
490 nm and 525 nm respectively for five minutes. D) Measurement of plasma membrane permeabilization was performed on TE85, TE85 + P2RX7B, MNNG-HOS and MNNG-
HOS + P2RX7B cells using ethidium bromide uptake, 15,000 cells in HBSS were incubated at 37 C with or without 10 lM of the P2RX7 inhibitor A740003 for 1 h. BzATP was
diluted in ultra-pure ethidium bromide to a final concentration of 300 lM BzATP and 100 lM ethidium bromide, the response was detected at 360 nm excitation and 580 nm
emission for 45 min after an initial 5-minute baseline reading, with readings taken every 2 min, HEK-293 + P2RX7A was used as a positive control. All data is from 3 biological
repeats with 6 technical replicates per experiment and were compared using an unpaired T-test, * = P < 0.05 ** = P < 0.01.
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examined histologically for signs of micrometastasis. We did not
detect metastasis in any of the 26 mice bearing MNNG-HOS pri-
mary OS tumours, but we did detect metastasis in mice bearing
MNNG-HOS + P2RX7B primary OS tumours. Out of 24 mice with
primary OS tumours, 5 (21%) had incidence of metastasis repre-
senting a significant difference (p = 0.0142) in the incidence of
detectable lung metastasis between the two cell lines (Fig. 4A &
4E). The P2RX7 antagonist had a tendency to reduce the incidence
of metastasis from 3/13 (23%) mice for vehicle to 2/11 (18%) mice
for A740003 (Fig. 4B & 4E) but this did not reach statistical
significance.
To further explore the role that P2RX7B plays in OS metastasis a
lung colonization model was performed where mice were tail vein
injected with either MNNG-HOS or MNNG-HOS + P2RX7B cells and
treated with either vehicle or A740003. The incidence of lung
metastasis using this model again tended to be higher in the mice
3
Fig. 2. The effect P2RX7B expression on TE85 and MNNG-HOS OS cell proliferation, adhesion, migration and invasion. Cell proliferation was assessed using an MTS assay over
7 days with absorbance taken on day 0,1,3,5 and 7. For inhibition studies A740003 was added on day 1 and measured on day 3. Ai) TE85 compared to TE85 + P2RX7B, Aii)
TE85 treated with A740003, Aiii) TE85 + P2RX7B treated with A740003 Aiv) MNNG-HOS compared to MNNG-HOS + P2RX7B Av) MNNG-HOS treated with A740003 Avi)
MNNG-HOS + P2RX7B treated with A740003. Cell adhesion was assessed by plating 7500 cells into a 96 well plate pre-coated with type 1 rat tail collagen and left for 4 h at
37 C, wells were washed 4 times with PBS and remaining attached cells lysed and detected using Quant-iTTM PicoGreen dsDNA Reagent. Fluorescence was detected at
excitation 485 nm and emission 530 nm. B) TE85 compared to TE85 + P2RX7B and MNNG-HOS compared to MNNG-HOS + P2RX7B. Migration was assessed by plating
200,000 cells into a 12 well plate and left 24 h to form a monolayer, the cells were incubated in 5 lg/ml mitomycin C for 2 h and then scratched down the centre of the well
using a 10 lL pipette tip, after washing twice with PBS the cells were left in medium containing 0.5% FBS with images taken every 2 h for 24 h All images were analysed, and
pseudo coloured using Tscratch software (Scale bar = 200 mm). Ci) Representative images for TE85 and TE85 + P2RX7B individually and when stimulated with BzATP, with the
corresponding wound closure data shown in Ciii and CiV. Representative images for MNNG-HOS and MNNG-HOS + P2RX7B individually and when stimulated with BzATP are
shown in Cii with the corresponding wound closure data shown in Cv and Cvi. For invasion cells were incubated in culture with 5 lg/ml mitomycin C and left for 2 h at 37 C.
They were seeded into a 24 well plate at a density of 100,000 cells in serum free medium containing 10 lM BzATP, in an upper fluoroblok chamber pre-coated with 1.5 mg/ml
matrigel. The medium in the lower chamber contained complete medium. After 24 h the upper fluoroblok transwells were washed twice in PBS and left for 30 min in calcein
AM (cell permeant dye) to stain live invaded cells. Images were taken covering 60% of the underside of the 24-well, this covered the entire surface of the smaller insert and
were analysed using Image J (Scale bar = 200 mm). Di) Representative images of TE85 compared with TE85 + P2RX7B when stimulated with BzATP with the number of invaded
cells shown in Dii. Representative images of MNNG-HOS compared with MNNG-HOS + P2RX7B when stimulated with BzATP are shown in Diii with the number of invaded
cells in Div. All data is from 3 biological repeats with 3–6 technical replicates per experiment and were compared using an unpaired T-test with migration slopes compared by
linear regression * = P < 0.05 ** = P < 0.01 *** = P < 0.001 **** = P < 0.0001.
Fig. 3. P2RX7B expression and P2RX7B inhibition on bone disease in an OS mouse model in vivo. Female BALB/c 7–9 week old mice were injected paratibially with either
MNNG-HOS or MNNG-HOS + P2RX7B cells (250,000 cells suspended in 20 mL PBS). Mice were then randomised into groups and treated with either vehicle or A740003 from
day 2, three times a week for 3 weeks via IP injection. Calliper measurements were taken on the final day as an end-point tumour measurement prior to euthanasia, the legs
were then collected and micro-CT scanned, the total bone volume starting from the point at which the femur wasn’t visible and the fibula meets the tibia was determined for
each leg and normalised to its own contralateral leg. Quantification of the bone volume (mm3) was done for all groups. n = 11–13 per group, the difference between the
tumour bearing and contralateral control leg determined by a paired t-test appropriate for the distribution of the data in the groups, and a Two-way ANOVA was used to
determine the effect of P2RX7B expression on tumour-induced changes in bone parameters. Ai) Representative micro-CT images of MNNG-HOS tumour bearing and
contralateral leg receiving vehicle and A740003 (Scale bar = 500 mm) with the corresponding bone volumes shown in Bi. Representative micro-CT images of MNNG-
HOS + P2RX7B tumour bearing and contralateral leg receiving vehicle and A740003 are shown in Aii) and the corresponding bone volumes shown in Bii.
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injected with MNNG-HOS + P2RX7B cells (4/12 or 33%) compared to the mice injected with MNNG-HOS (1/12 or 8%) (Fig. 4C & 4F,
3
Fig. 4. P2RX7B expression increases OS metastasis in the lungs of MNNG-HOS and MNNG-HOS + P2RX7B paratibial and tail vein injected mice. Female BALB/c 7–9 week old
mice were injected paratibially with 250,000 cells suspended in 20 mL PBS of either MNNG-HOS or MNNG-HOS + P2RX7B cells. Mice were then randomised into groups and
treated with either vehicle or A740003 from day 2, three times a week for 3 weeks via IP injection. For the tail vein model the same treatment regime was used after 1.5
million cells were injected. The mice were then euthanised and the lungs embedded into wax blocks sectioned and 6 lm sections cut every 100 lm deep to cover the entire
lung. They were then stained using H&E and visualised using a light microscope. A) Total number of OS lung metastasis in MNNG-HOS and MNNG-HOS + P2RX7B tumour
bearing mice in the paratibial model. B) Number of OS lung metastasis in MNNG-HOS and MNNG-HOS + P2RX7B tumour bearing mice across treatment groups in the
paratibial model. C) Total number of OS lung metastasis in MNNG-HOS and MNNG-HOS + P2RX7B injected mice in the tail vein model. D) Number of OS lung metastasis in
MNNG-HOS and MNNG-HOS + P2RX7B injected mice across treatment groups in the tail vein model. E) Representative images of the lungs from MNNG-HOS and MNNG-
HOS + P2RX7B vehicle and A740003 treated in the paratibial model F) from MNNG-HOS and MNNG-HOS + P2RX7B vehicle and A740003 treated in the tail vein model (Scale
bar = 50 mm).
Fig. 5. Heat map based hierarchical cluster analysis of DE genes (y-axis) across cell type (y-axis). Z-score refers to high (red) and low (blue) gene expression using normalised
values when compared to the mean of total sequencing reads. Heat maps are accompanied by STRING analysis to show gene–gene connections at high confidence (scores
between 0.7 and 0.9). Line colour connecting genes indicate the known and predicted interactions. Blue lines represent data from curated databases. Pink lines represent data
from experiments. Green lines represent gene neighbourhoods. Black lines represent co-expressed genes. A) MNNG-HOS + P2RX7B cells versus activated receptors using
BzATP. B) MNNG-HOS + P2RX7B cells versus inhibited receptor using A740003 antagonist. Potential off target effects were considered by performing RNA-seq in MNNG-HOS
cells (Supplementary File). Each transcript presented has passed log2 fold change  2, p  0.05 and FDR  5% parameters.
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p = 0.0658). Treatment with the P2RX7 antagonist tended to
reduce the incidence of metastasis to none in the MNNG-HOS cell
injected mice, and from 3/6 (50%) to 1/6 (17%) for MNNNG-
HOS + P2RX7B injected mice (Fig. 4D & 4F), although this did not
reach statistical significance.
3.5. P2RX7B inhibition drives downregulation of FN1/LOX/PDGFB/
IGFBP3/BMP4 axis
To determine the downstream pathways contributing to the
observed effects of P2RX7B signalling in OS cells in vitro and
in vivo, we took a hypothesis free approach using RNA-seq. We per-
formed heat map based hierarchical cluster analysis on DE genes
unique to MNNG-HOS + P2RX7B cells when either treated with
BzATP (Fig. 5A) or the antagonist A740003 (Fig. 5B). These genes
were cross-referenced with several control cell lines to ensure that
our data was derived from P2RX7B activation/inhibition and not
from off target effects (Supplementary File). P2RX7B activation
and antagonism were shown to drive independent responses, with
antagonism specifically demonstrating a more potent biological
response when in the context of cancer, showing a visibly higher
number of genes affected and these are strongly related to cancer
progression (Fig. 5 A-B). STRING analysis of gene–gene connections
at high confidence level revealed an axis of downregulated genes in
the P2RX7B antagonist treated MNNG-HOS + P2RX7B cells
(Fig. 5B). This analysis revealed that P2RX7B antagonism downreg-
ulated an FN1/LOX/PDGFB/IGFBP3/BMP4 axis, which contains genes
that are all known cancer drivers when upregulated [51].
4. Discussion
Despite being the most common type of primary bone cancer
affecting children and adolescents, treatment options for OS have
remained stagnant for the last 40 years or more. The overall five-
year survival for all OS patients is 60% largely due to the fact that
many patients relapse from chemoresistance or have metastasis
on diagnosis reducing the survival rate in these patients to around
20% [3]. Treatment options are brutal and life changing, with sur-
gery often leading to permanent disability and chemotherapy hav-
ing significant side effects including infertility, cardio-, nephro-
and hepatic- toxicity. More targeted treatment options are needed
to effectively treat OS patients with fewer treatment side effects.
We and others have previously reported the role of P2RX7
purinergic signalling in both the bone microenvironment and OS
[8,9,15,44], and this particular receptor has been increasingly
implicated in cancer progression in various cancer types [52]. In
this study we have built upon these observations and detailed
the role of the P2RX7B splice variant specifically in OS. Having pre-
viously demonstrated that the cell line TE85 does not express func-
tional P2RX7 [15,44] we chose to use this cell line as well as the
sub-clone MNNG-HOS to investigate the effect of the splice variant
P2RX7B alone on OS cell behaviour. Prior to transfecting these cells
with the P2RX7B, we confirmed that neither cell line expressed
P2RX7 at the mRNA level. This finding is in direct contrast to a
recent study, published during our own ongoing studies, which
suggested that MNNG-HOS cells highly express P2RX7 [30]. We
also scrutinised publicly available datasets to determine the rela-
tive levels of P2RX7 in the HOS family of OS cell lines and found
that HOS, MNNG-HOS, KHOS and 143B cells all had low or non-
existent expression of P2RX7, further confirming our observations.
Following transfection of P2RX7B into TE85 and MNNG-HOS
cells, end point PCR and qRT-PCR confirmed robust mRNA expres-
sion. There was also a substantially increased calcium response in
P2RX7B transfected clones when stimulated with BzATP. Control
cells also gave a slight increase in calcium response upon BzATP
treatment, however this was not to the same extent as in
P2RX7B and may be due to activation of other BzATP-sensitive
P2 receptors [53]. We also checked BzATP-induced pore formation
in these cells, as despite P2RX7B not having the typical pore forma-
tion response due to a truncated C terminal region known to be
responsible for the pore, we have previously demonstrated that
co-expression of P2RX7A and P2RX7B does lead to pore formation
[15]. This further demonstrates a lack of endogenous P2RX7A
expression in these cells, that in our clones the calcium increase
relates to P2RX7B and in these clones a ‘‘non-functional” pheno-
type is present [26].
We have previously shown that when the full length P2RX7A
variant was expressed alone in TE85 cells a growth advantage
was observed, yet when both the P2RX7A and the P2RX7B variant
were expressed together, although this enabled the typical P2RX7
pore formation, there was no further increase in growth. However,
the strongest growth advantage was observed when the P2RX7B
variant alone was expressed, prompting us to further investigate
this in this study [15].We confirmed a strong growth advantage
when P2RX7B was expressed in TE85 as expected and also
MNNG-HOS cells. This growth advantage was observed in low
serum conditions without exogenous activation of the receptor.
However, we have previously shown that in Te85 cells expressing
P2RX7 variants the enhanced growth advantage was diminished in
the presence of apyrase suggesting that there is basal extracellular
release of ATP by these cells to a concentration capable of activat-
ing P2RX7B [15]. The finding that the P2RX7 antagonists A740003
could significantly reduce this growth advantage offers promise for
inhibiting P2RX7B mediated effects.
We next sought to determine the effect of P2RX7B expression
on the ability of OS cells to leave the primary tumour site, invade
surrounding tissues and spread to distant sites to form metastasis
– the so called ‘‘invasion-metastasis cascade” [54]. This is particu-
larly pertinent in OS and other highly metastatic cancers, as the 5-
year survival rate is drastically reduced in patients with metastasis
[3]. Using established in vitro techniques, we found that P2RX7B
expression reduced the ability of OS cells to adhere to a collagen
ECM. Non-cancerous cells are normally tightly adherent to their
ECM and also to each other – changes in cell-to-cell and cell-to-
matrix adhesion is the first fundamental step in the metastatic cas-
cade. E-cadherin is known to be pivotal in the control of cancer cell
adhesion and spread, and it has previously been demonstrated that
PX7R activation downregulates E-cadherin in breast cancer cells
[55] Loss of E-cadherin mediated adhesion is also frequently asso-
ciated with invasion and migration. Similar mechanisms involving
cadherin signalling could be responsible for the P2RX7B-induced
loss of adhesion in OS cells. Similar to the enhanced growth, acti-
vation of P2RX7B with the potent P2RX7 agonist BzATP, demon-
strated increased invasion and migration rates in OS cells.
Invasion requires the expression of various matrix metallopro-
teinases (MMPs) that are capable of digesting the ECM, allowing
the cells to break away from the primary site and interact with
tumour-associated stromal cells such as macrophages [51]. Activa-
tion of P2RX7 has been shown to induce the release of MMP13 in
breast cancer cells [55] and has long been known to be responsible
for the ATP-induced rapid release of MMP-9 from human
peripheral-blood mononuclear cells [56]. This data further sup-
ports a pro-tumorigenic role of P2RX7 in OS as demonstrated pre-
viously [15,30], but adds new knowledge that the B variant alone
plays a role in the metastasis cascade in OS cells in vitro.
Encouraged by the in vitro data, we next examined the role of
P2RX7B in OS in vivo. As previously mentioned, the TE85 cell line
does not produce tumours in mice therefore the MNNG-HOS cell
lines only were used. Assessment of the growth of the primary
tumour using calliper measurements and Ki-67 staining did not
show any effect of P2RX7B expression or any effect of the P2RX7
antagonist A740003 on the final tumour volume or proliferation
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status. This was a surprising finding given the in vitro data and the
previous study from Zhang et al. who showed a 50% reduction in
the growth of intra-tibial MNNG-HOS tumours with A740003
treatment [30]. The differences between our data and theirs maybe
explained by the different OS models used (paratibial versus intra-
tibial injection of cells), timing of treatment (2 days post cell injec-
tion versus  10 days) and also potential differences in the paren-
tal MNNG-HOS cell lines. As stated above we could not find any
P2RX7 mRNA expression or typical function in the MNNG-HOS
cells we used. When analysing the resultant bone disease in our
OS model, expression of P2RX7B significantly affected the bone
disease observed, with A740003 reducing the extent of the tumour
induced bone disease in both MNNG-HOS + P2RX7B and MNNG-
HOS such that the bone volume was no longer significantly
increased compared to the contralateral leg. Whilst this is in keep-
ing with the positive effect of P2RX7 antagonism on OS-induced
bone disease previously reported, it is important to note again
the difference between the two models. Here we show for the first
time the specific involvement of P2RX7B in OS induced bone dis-
ease; that MNNG-HOS + P2RX7B cells produce an osteoblastic phe-
notype with formation of ectopic bone and so an increase in total
bone volume which was reduced by treatment with A740003.
Zhang et al show that the MNNG-HOS cells they used produced
predominantly a lytic bone disease leading to reduced BV/TV
which was also rescued with A740003 treatment [30]. We also
observed a reduction in the ectopic bone formation in the parental
MNNG-HOS cells when treated with A740003. Considering that in
our hands these cells do not express endogenous, functional P2RX7
receptors and the lack of effect on tumour size, the effect of
A740003 may be mediated by the bone microenvironment itself,
as opposed to a direct tumour driven effect. We and others have
shown that both osteoblasts and osteoclasts express functional
P2RX7 receptors [8], and the P2RX7 knockout mice display a bone
phenotype [57-60]. Therefore treatment with A740003 could be
affecting the resident bone cells and reducing the resultant bone
disease in both subtypes of OS. Targeting the bone microenviron-
ment in OS is a valid strategy, with other mediators of osteoblast
and osteoclasts being previously proposed as potential therapeutic
targets [61].
The five year survival rate for OS in the presence of secondary
metastases is around 20%. In addition, a quarter of patients pre-
senting with detectable lung metastasis relapse. Gaining further
insight into the potential mechanisms or predictors of OS metasta-
sis is of paramount importance. By examining the lungs of the
tumour bearing mice we found that P2RX7B expression in the pri-
mary tumour led to a significantly higher incidence of lung metas-
tasis. This is in contrast to the lungs of the parental MNNG-HOS
tumour bearing mice which showed no metastasis, in keeping with
the previous observations that MNNG-HOS cells in vivo have no or
very low incidence of pulmonary metastasis [45,47]. Taken
together with the in vitro data of decreased adhesion with
increased invasion and migration abilities of the MNNG-
HOS + P2RX7B cells and the minimal effect on tumour growth seen
in our in vivo studies, these data support a role for the P2RX7B in
the metastasis cascade in OS.
Previous studies in other cells types have elucidated various sig-
nalling pathways responsible for P2RX7 mediated effects such as
via SK3 potassium channels and Cathepsin B [17], Cdc42 activity
and the acquisition of a mesenchymal phenotype in breast cancer
cells [21], Epithelial–mesenchymal transition (EMT) via SMAD2
phosphorylation in glioblastoma stem cells [19] and EMT/
invasion-related genes Snail, E-cadherin, Claudin-1, IL-8 and
MMP-3 as well as PI3K/AKT and ERK1/2 in prostate cancer cells
[18]. Whilst Zhang et al. also showed P2RX7 activation in OS cells
promoted epithelial to mesenchymal transition and activated
PI3K/Akt/GSK3b/b-catenin and mTOR/HIF1a/VEGF signalling [30].
Therefore, to try and elucidate further the pathways downstream
of P2RX7B in OS we utilized a hypothesis-free RNA-seq approach.
Using this methodology we revealed a set of genes that are differ-
entially expressed upon both P2RX7B activation and antagonism.
Antagonism of P2RX7B showed a more potent response in the con-
text of cancer leading to a higher number of genes affected, but
also suggesting that P2RX7B has activation state-dependent roles.
These genes were strongly related to cancer and STRING analysis
revealed a unique axis of downregulated genes in the antagonist
treated MNNG-HOS + P2RX7B cells. Within this axis the genes
FN1, LOX, PDGFB, IGFBP3 and BMP4 are known to promote cancer
progression when upregulated in various cancer types. Roles for
these genes/gene products in OS have also been reported: FN1
was shown to be upregulated in chemoresistant OS cells, was
related to unfavourable prognosis and its inhibition greatly
increased the sensitivity of OS cells to doxorubicin in vitro and
in vivo [62]. LOX (Lysyl Oxidase) has been suggested to be tumour
suppressor in OS [63], however we and others have shown that it is
linked to hypoxia and plays a pro-tumorigenic role in cancers that
metastasis to bone, inducing the pre-metastatic niche both in soft
tissues such as lungs and in bone via formation of osteolytic lesion
[64]. PDGFB is also linked to hypoxia and has been shown to be
involved in OS cell proliferation and migration [65], and IGFBP3
has also been shown to stimulate OS migration [66]. The BMP4 pro-
tein, part of the bone morphogenetic family which are known crit-
ical regulators of bone formation and remodelling, has recently
been shown to be the most frequently expressed BMP in muscu-
loskeletal tumours, including OS, in a recent study of 1,361
patients with 22 types of musculoskeletal tumours [67]. Elucidat-
ing the interplay between P2RX7B and these signalling pathways
could reveal common targets at which they converge and that
may prove to be fundamental in OS progression and metastasis.
Further studies should look to determine the effect of combination
treatments (both within this axis and with current OS drugs) that
may prove to be more efficacious than single agent treatments.
Combining treatments for signalling pathways specifically
involved in OS would lead to kinder, less harsh treatments for
the patient, fewer relapses and a better overall prognosis.
5. Conclusion
In summary we present data for the first time that the specific
P2RX7B isoform, which has a distinct non-functional phenotype
compared with full length P2RX7, is associated with OS progres-
sion, bone disease and metastasis. Future studies exploring the
therapeutic targeting of P2RX7 need to pay particular attention
to the isoforms being targeted as well as the OS subtype.
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